“Bimekizumab versus Ustekinumab Efficacy Across Subgroups of Patients with Moderate to Severe Plaque Psoriasis: Results from the Multicenter, Randomized, Double-Blinded Phase 3 BE VIVID Trial”, J of Skin, vol. 5, no. 1, p. s16, Jan. 2021, doi: 10.25251/skin.5.supp.16.